Assessment of treatment efficacy of diphenylcyclopropenone (DPCP) for alopecia areata

Kutlubay, Zekayi; Sevim, Ayşegül; Aydın, Övgü; Vehid, Suphi; Serdaroğlu, Server

doi:10.3906/sag-1807-230

Cited by 10 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Although the exact mechanism of topical immunotherapy on AA remains unknown, an immunomodulatory effect on inflammatory infiltration around the hair follicle is considered to play a role. 5,8,9 DPCP is an experimental sensitizing agent for topical immunotherapy that is most often used to treat AA. 8 However, there is a risk associated with the use of DPCP in AT patients with AD in that DPCP can exacerbate AD by inducing a nonspecific allergic reaction.…”

Section: Discussionmentioning

confidence: 99%

“…5,8,9 DPCP is an experimental sensitizing agent for topical immunotherapy that is most often used to treat AA. 8 However, there is a risk associated with the use of DPCP in AT patients with AD in that DPCP can exacerbate AD by inducing a nonspecific allergic reaction. Patients with severe AD with many T cells activated, including T helper 2 cells, may experience severe systemic nonspecific allergic reactions even in DPCP sensitization.…”

Section: Discussionmentioning

confidence: 99%

“…However, since DPCP is a contact allergen, it has the potential to exacerbate AD. 8 Herein, we report a patient with promising results following AIT for AT with severe AD.…”

Section: Introductionmentioning

confidence: 93%

See 2 more Smart Citations

Allergen‐specific immunotherapy improves alopecia totalis in a severe atopic dermatitis patient

Kwon

Park

Kim

et al. 2023

The Journal of Dermatology

View full text Add to dashboard Cite

House dust mite (HDM) is the most common allergen exacerbating atopic dermatitis (AD), and allergen‐specific immunotherapy (AIT) using HDM exhibited significant improvements in previous studies. Alopecia can occur as a complication of AD. Alopecia totalis (AT), a severe form of alopecia areata (AA), does not respond well to treatment and the chance of full recovery is less than 10%. For extensive hair loss, topical immunotherapy such as diphenylcyclopropenone (DPCP) is used as the first‐line treatment. However, since DPCP is a kind of contact allergen, it has the potential to exacerbate AD. A 38‐year‐old man with AD and AA visited our clinic with symptoms worsening from 3 months ago. Although taking oral methylprednisolone (8 mg/day) and cyclosporine (100 mg/day) for 3 months, he has lost over 90% of his hair and the Eczema Area and Severity Index (EASI) was 43. Total serum immunoglobulin E (IgE) levels were 4454 kU/L (normal <100 kU/L) and the specific IgE levels for Dermatophagoides pteronyssinus and Dermatophagoides farinae following ImmunoCAP® were 20.8 and 37.4 kU/L, respectively. This patient did not respond well to previous treatment and was reluctant to use long‐term steroids, so subcutaneous AIT using HDM was administered along with oral cyclosporine (100 mg/day). Topical tacrolimus was also applied to the AD lesions throughout the body. To reduce itching, nonsedative antihistamines were used if necessary. Hair loss was almost completely improved 1 year after the AIT initiation and the skin lesions of AD also improved (EASI 2.4). The specific IgE levels for D. pteronyssinus and D. farinae were 3.73 and 7.16 kU/L, respectively. Herein, we report a patient with promising results following AIT for AT with severe AD. In severe alopecic patients with AD refractory to conventional treatment, including immunosuppressants, AIT could be considered as a treatment option.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Allergen‐specific immunotherapy improves alopecia totalis in a severe atopic dermatitis patient

Kwon

Park

Kim

et al. 2023

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…21 Marmesin, as a natural furan coumarin compound, has the functions of anti-aging, 22 antifungal, 23,24 inhibiting the proliferation of vascular endothelial cells and protecting vascular endothelium. 25 Diphenylcyclopropenone (DPCP) is a topical immune response modifier, which induces contact dermatitis with DPCP and leads to hair regeneration, so it is used in the study of alopecia areata, 26,27 the study showed that DPCP can effectively treat patients with alopecia areata via TSLP/OX40L/IL-13 pathway. 28 Angelic Acid is a substance in the essential oil of Anthemis nobilis, which is helpful for wound healing and has sedative properties as psychotropic drugs.…”

Section: Discussionmentioning

confidence: 99%

Study on Anti-Inflammatory Mechanism of Angelica pubescens Based on Network Pharmacology and Molecular Docking

Ren

Mo³

et al. 2022

Natural Product Communications

View full text Add to dashboard Cite

References and data show that AP has a certain effect on alleviating inflammation. Based on the methods of network pharmacology and molecular docking, this paper predicts the potential mechanism of anti-inflammatory effect of the effective components. Methods: Active components and target genes of AP were screened out by SymMap, an associated database of TCM syndromes. First, screen out the active components according to the setting conditions, and its molecular structure file was obtained from the PubChem database. The target genes of anti-inflammatory effect were obtained from GeneCards database with “anti-inflammation effect” as the keyword, and then the common gene targets between AP and anti-inflammatory effect were screened. The PPI network diagram was constructed with Cytoscape 3.80 software to screen the core genes. The GO function and KEGG pathway of the core genes were enriched and analyzed by David database; 3D view of proteins encoded by the core gene from the PDB database, conduct molecular docking between the active components and the core proteins in Auto Dock Vina software, and made a heat map with binding free energy. Results: The main anti-inflammatory components were O-Acetylcolumbianetin, isoindigo, Nodakenetin, Marmesin, Diphencyprone; The core targets are TNF, VEGFA, IL6, TP53, IL1B, ESR1, MMP9, PPARG, Jun, CASP3, PTGS2. AP participated in cytokine-mediated signaling pathway, response to drug, positive regulation of gene expression, and other processes by regulating the combination of extracellular space, cell surface with protein and enzyme, and then exert anti-inflammatory activity. The signal pathways mainly involved IL-17 signaling pathway, hepatitis B, TNF signaling pathway, inflammatory bowel disease, rheumatoid arthritis, etc.; Through molecular docking, it was found that the key targets were MMP9, TNF, PTGS2, ESR1, JUN, and PPARG, while the active components which ha,d a strong effect on these genes were O-Acetylcolumbianetin, isoindigo, Nodakenetin, Marmesin, Diphencyprone. Conclusion: This study used network pharmacology and molecular docking methods to predict the potential active components, target genes, and signal pathways of the anti-inflammatory effect of AP, so as to provide a theoretical reference for the follow-up experimental research and clinical treatment of AP.

show abstract

“…In 10 selected studies, side effects from DPCP were not mentioned, although some studies have shown good results with acceptable side effect profiles (36). In 2020, a study conducted by Kutlubay, children over 5 years of age were also included and the treatment results or safety parameters were similar to those of the adult patients (37).…”

Section: Discussionmentioning

confidence: 99%

A systematic review on the treatment of pediatric severe alopecia areata by topical immunotherapy or Anthralin (contact sensitization) or low‐level light/laser therapy (LLLT): focus on efficacy, safety, treatment duration, recurrence, and follow‐up based on clinical studies

Behrangi

Roohaninasab

Sadeghzadeh‐Bazargan

et al. 2021

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Introduction: Alopecia areata (AA) in its extensive and severe forms is treatmentchallenging, especially in pediatrics.Method: A PRISMA-compliant systematic review of seven electronic databases was searched by the terms "alopecia areata," "pediatric," "topical immunotherapy," "Anthralin," and "light therapy" from inception until March 2021. All the alternative names of the disease and therapies have been included in the search terms. 790 articles went to title abstract review by two independent reviewers. In the subsequent level, a review of the full text of studies was conducted.Results: Finally, 10 relevant articles in terms of content structure, subject coverage, and purpose, were selected for further review. The highest percentages of complete hair regrowth were 79.6% and 63.61% by SADBE (topical immunotherapy) and laser therapy. By Anthralin (contact sensitization), the complete response rate was below 50% (between 30 and 35%). Regarding average response, the most effective methods were local immunotherapy (with an average effectiveness of 53.8%), laser therapy (52.55%), and the use of Anthralin-induced contact dermatitis (30.86%), respectively. However, recurrence rate-after treatment with induced contact dermatitis by topical medications like Anthralin (contact sensitization)-was lower (mean 43.53%) in comparison with local immunotherapy (57%). In topical immunotherapy, light base therapy, and contact sensitization, the highest percentage of complete hair regrowth and the average response rate were (63.61% and 52.55%), (79.6% and 53.8%) and (32% and 30.8%), respectively. These methods are considered safe in children. Conclusion:A high and more than 50% efficacy in hair regrowth could be expected by topical immunotherapy and light/laser therapy method. No serious side effects

show abstract

Assessment of treatment efficacy of diphenylcyclopropenone (DPCP) for alopecia areata

Cited by 10 publications

References 27 publications

Allergen‐specific immunotherapy improves alopecia totalis in a severe atopic dermatitis patient

Allergen‐specific immunotherapy improves alopecia totalis in a severe atopic dermatitis patient

Study on Anti-Inflammatory Mechanism of Angelica pubescens Based on Network Pharmacology and Molecular Docking

A systematic review on the treatment of pediatric severe alopecia areata by topical immunotherapy or Anthralin (contact sensitization) or low‐level light/laser therapy (LLLT): focus on efficacy, safety, treatment duration, recurrence, and follow‐up based on clinical studies

Contact Info

Product

Resources

About